CYP7A1 and metabolic dysfunction-associated steatotic liver disease: Moreover, fasting plasma 7α-hydroxy-4-cholesten-3-one (C4), a marker used to monitor CYP7A1 enzymatic activity [36], is elevated in NAFLD patients, supporting the notion of increased BA synthesis due to lower FXR activity [22,37].